Special Issue

Antimicrobial Peptides: Therapeutic Potentials

Message from the Guest Editor

Antimicrobial peptides (AMPs) have been recognised for their ability to kill multidrug resistant bacteria and do not easily induce resistance, two features that makes them very attractive as drug candidates. In addition, the overall peptide drug market is steadily growing, from US$18.9 billion in 2013 to US$23.7 billion in 2020. This has led to improved scale up technologies and new large-scale GMP facilities and innovative drug administration regimes. Supported by the price increase for novel antimicrobials and the “ready to use” technology, antimicrobial peptides can become a viable option for urgently needed new antimicrobial drugs. In the last two decades of AMP research, it became clear that these molecules have multiple biological activities, like antimicrobial, antiparasitic, anticancer and immunomodulatory. In the same time period, multiple targets of AMPs for their antibacterial activities were discovered. In this Special Issue, we invite you to send contributions concerning any biological activities related to the therapeutic potential of antimicrobial peptides, including direct and indirect modes of action.

Guest Editor

Dr. Kai Hilpert

Institute of Infection and Immunology, St George’s, University of London, London SW17 0RE, UK

Deadline for manuscript submissions

closed (30 September 2020)

Microorganisms

an Open Access Journal by MDPI

Impact Factor 4.2
CiteScore 7.7
Indexed in PubMed

mdpi.com/si/24585

Microorganisms
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
microorganisms@mdpi.com

mdpi.com/journal/microorganisms

Microorganisms

an Open Access Journal by MDPI

Impact Factor 4.2
CiteScore 7.7
Indexed in PubMed

mdpi.com/journal/microorganisms

About the Journal

Message from the Editor-in-Chief

"Microorganism" merges the idea of the very small with the idea of the evolving reproducing organism is a unifying principle for the discipline of microbiology. Our journal recognizes the broadly diverse yet connected nature of microorganisms and provides an advanced publishing forum for original articles from scientists involved in high-quality basic and applied research on any prokaryotic or eukaryotic microorganism, and for research on the ecology, genomics and evolution of microbial communities as well as that exploring cultured microorganisms in the laboratory.

Editor-in-Chief

Dr. Nico Jehmlich
Department of Molecular Toxicology, UFZ-Helmholtz Centre for Environmental Research, 04318 Leipzig, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, PubAg, CAPlus / SciFinder, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Microbiology) / CiteScore - Q1 (Microbiology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.2 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).

MDPI